DERMATOLOGY company Botanix Pharmaceuticals, ASX-listed, has announced positive results for its BTX 1204 atopic dermatitis study.
The four-week research demonstrated BTX 1204 was twice as effective as the vehicle for dermatitis signs with efficacy still increasing at the four week timepoint.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jun 18
